|Bid||86.93 x 900|
|Ask||86.94 x 1200|
|Day's Range||86.90 - 87.84|
|52 Week Range||73.20 - 95.00|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||17.87|
|Forward Dividend & Yield||2.83 (3.17%)|
|1y Target Est||N/A|
Hoy Health launched less than two years ago, but sees strong growth potential in paving the way to the Latin American health care market.
On the stump, if there's one thing that both Republican and Democratic politicians have long claimed to support, it's lower drug prices. And when rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed…some fairly, and some not (as we'll see).That's just what happened in the past week.House Speaker Nancy Pelosi has a tougher proposal on her agenda than, say, President Trump. While the Trump administration is more interested in importing lower-priced versions of the drugs from Canada, Pelosi wants to apply direct pressure to pharmaceutical companies.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSpecifically, Pelosi wants to allow the Dept. of Health & Human Services to negotiate prices for Medicare Part D drug plans directly with drug manufacturers. (That would, effectively, eject pharmacy benefit managers and insurance companies from the negotiating table.)Several biotech stocks have taken big hits on the regulatory rumors. Some of the Big Pharma crowd even showed up on the list of three-year lows last week! Let's review - because while some deserve to be sold, one big mover is actually on my Top 5 Stocks list for Breakthrough Stocks. * 7 Discount Retail Stocks to Buy for a Recession First we have Biogen (NASDAQ:BIIB), a potential target of Pelosi's proposal. With its famously pricey drug for spinal muscular atrophy, Spiranza, Biogen may well come into Democrats' crosshairs here. BIIB stock dropped sharply last Friday and again on Thursday.You may think that with pricing like $750,000 for your first year of Spiranza, Biogen would be printing money. But Spiranza just picked up a competitor from Novartis (NYSE:NVS). And below is the full picture on BIIB stock from my Portfolio Grader:While Biogen passes some of my profitability tests, it gets an F for Earnings Momentum, and Sales Growth is lackluster as well. Most concerning is the fact that BIIB stock got a D for its Quantitative Grade - my proprietary measure of institutional buying pressure.Regeneron Pharmaceuticals (NASDAQ:REGN) is looking even worse. The stock got off to a rough start this week, and while it's clawed back somewhat, it's still down 8% in the past month. For its part, Regeneron has a cholesterol drug (Praluent) that was so expensive that it eventually succumbed to pressure, reduced prices by 60%, and yet it still costs $5,850 a year.Here's REGN's Report Card:As you see above, Regeneron just does not measure up on Operating Margin Growth, Earnings Growth, Earnings Momentum or its Quantitative Grade.Then there's Repligen (NASDAQ:RGEN). While it may have a similar name and ticker, RGEN has much stronger fundamentals. Shares took an even bigger hit - but this is a much more interesting case.Repligen is a unique biotech: This company actually has no drugs of its own, but rather, its products are used in drug manufacturing.Repligen hit the biotechnology scene back in 1981, as it started to develop Protein A ligands to aid in the production of biologic treatments. The company has expanded rapidly since then, and was even named one of the Top 100 fastest-growing companies in the U.S. in 2018. Today, along with Protein A ligands, Repligen offers several products and solutions to enhance the production of biologic drugs.Strong demand for Repligen's biologic solutions was apparent in the company's second-quarter earnings report. The company reported 48% annual revenue growth and 121.4% annual earnings growth. Plus, second-quarter earnings of $0.31 per share crushed estimates for $0.25 per share by 24%.Given the strong second-quarter results, analysts have increased full-year 2019 forecasts in the past two months. Analysts are forecasting 32.9% annual earnings growth and 37.1% annual sales growth.This all makes for a very impressive Report Card on RGEN, as you see here:So, when this kind of stock drops as hard as RGEN just did, I view it as a chance to pick up shares at "bargain basement" prices for a great, long-term play. There's Something Else That Sets These Breakthrough Stocks ApartIf you take a look at RGEN stock, you'll notice its much smaller market cap of $4 billion, versus giant biotech stocks like BIIB and REGN with $30 billion (or more)!If you're a growth investor - and I certainly am; I've made my career this way - then you've got to look at elite small-caps like this. With growth statistics like RGEN's (and my other Breakthrough Stocks), the sky is the limit.RGEN is 4 on my list of Top 5 Stocks. To get my buy price - and the rest of the list - check out Breakthrough Stocks now. When you do, you'll learn all about my "Quantum A" system for identifying the best small-cap investments.Ultimately, spotting the right investment is simple. You buy when the company achieves a Quantum A …and you sell when it disappears.You don't fall in love. You certainly don't fall for hype. You may return to that stock someday - but with my system, you know exactly when it's time to take profits off the table.That's why I always say: There's no luck and very little skill behind my own success - just hard work. And the result: a proprietary system for picking the best investments of the day. It's made it easy to nab market-beating returns - for double your money (or better).I'm eager to show you what my system is picking up now. Click here to find out more.Louis Navellier had an unconventional start, as a grad student who accidentally built a market-beating stock system -- with returns rivaling even Warren Buffett. In his latest feat, Louis discovered the "Master Key" to profiting from the biggest tech revolution of this (or any) generation. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Big IPO Stocks From 2019 to Watch * 7 Discount Retail Stocks to Buy for a Recession * 7 Stocks to Buy Benefiting From Millennial Money The post 3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector appeared first on InvestorPlace.
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
The organizations plan to continue developing CAR T-cell therapies together, but on a more narrow scale.
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.
The deal gives RegenxBio an option for exclusive, worldwide commercial licensing rights to the biopharma’s SCS Microinjector, its delivery method for gene therapies.
Novartis Chief Executive Vas Narasimhan, facing an uproar over data manipulation involving $2.1 million gene therapy Zolgensma, pledged on Monday to tell regulators quickly if credible questions emerge in future over data integrity. Novartis has said it knew of discrepancies in Zolgensma data it had submitted to the U.S. Food and Drug Administration before it won approval for the world's most expensive medicine in May, but delayed informing regulators until June 28 while it completed an internal investigation. While the FDA has concluded Zolgensma is safe and effective and should remain on the market, the U.S. drug watchdog raised questions about the timing of Novartis's disclosure.
Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.
The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.
The FDA grants a Breakthrough Therapy status to Novartis' (NVS) capmatinib for the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type. Novartis aims to file for U.S. approval for oral capmatinib later this year as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), the Basel-based company said on Friday.
AstraZeneca's (AZN) Tagrisso gets a marketing approval in China for the first-line treatment of advanced or metastatic non-small cell lung cancer in patients with tumors having EGFR mutations.
As Swiss drug giant Novartis AG deals with continuing fallout from a data manipulation controversy related to its acquisition of a drug startup AveXis, it's considering acquiring another young company from a trusted partner.
Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.
Novartis AG's gene therapy for blindness, Luxturna, is recommended for use on England's public health service, the country's healthcare cost-effectiveness watchdog NICE said on Tuesday. Novartis owns the rights to sell the one-time gene therapy developed by Spark Therapeutics outside the United States.
Vertex Pharmaceuticals has struck a deal to acquire local diabetes-focused startup Semma Therapeutics, marking another substantial pivot for the company as CEO Jeff Leiden's tenure comes to a close.